Table 1

Key eligibility criteria

Inclusion criteria
  1. Female patients ≥18 years

  2. Histologically confirmed epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, high grade, serous, or endometrioid, with the exception of mucinous, clear cell, and carcinosarcoma histologies

  3. Performance status <2 (see online supplemental appendix 2)

  4. Documented International Federation of Gynecologic Oncology (FIGO) 2014 stage IIIB–IIIC–IVA unsuitable for complete primary cytoreductive surgery (confirmed by open laparoscopy or by laparotomy (not mandatory for stage IVA))

  5. Patient must be judged resectable after three courses of neoadjuvant chemotherapy

  6. Sufficiently good bone marrow, liver, and renal function to receive chemotherapy and subsequently undergo surgery

 Exclusion criteria
  1. Mucinous, clear cell, carcinosarcoma, and low-grade serous carcinoma histologies

  2. Synchronous or previous other malignancies in the 3 years prior to starting the study treatment, with the exception of adequately treated non-melanomatous skin cancer or carcinoma in situ (of the cervix or breast or other sites)

  3. Patients with brain metastases, seizures not controlled with standard medical therapy, or a history of cerebrovascular accident (stroke) or transient ischemic attack or subarachnoid hemorrhage in the 6 months before enrollment on this study

  4. Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise adherence to the protocol (including, but not limited to, impaired cardiac function or clinically significant cardiac diseases, active or uncontrolled infections, HIV-positive patients receiving antiretroviral therapy, uncontrolled diabetes, cirrhosis, chronic active or persistent hepatitis, impaired respiratory function requiring oxygen dependence, serious psychiatric disorders)

  5. Pregnant or breastfeeding women.